Study of Sarilumab With Immune Checkpoint Inhibitor Rechallenge in Patients With Clinically Significant Immune Related Adverse Events (IRIS)
Phase II Study of Sarilumab With Immune Checkpoint Inhibitor Rechallenge in Patients With Clinically Significant Immune Related Adverse Events (The IRIS Trial: Immune Checkpoint Inhibitor Rechallenge Involving Sarilumab)
The study will enroll patients with history of malignancy treated with immune checkpoint inhibitors (ICI) that have developed a grade 2 or higher immune related adverse event requiring treatment discontinuation as deemed by the patient's treating physician. Patients will be sequentially enrolled into the single-arm study after meeting the pre-specified eligibility criteria
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ2
連絡先と場所
研究連絡先
研究連絡先
- 名前:Danielle Wendler
- 電話番号:410-502-5140
- メール:JHCTN@jhmi.edu
研究連絡先のバックアップ
- 名前:Chelsea Miralles
- 電話番号:410-955-9923
- メール:cmirall1@jhmi.edu
研究場所
-
-
Maryland
-
Baltimore、Maryland、アメリカ、21287
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
-
コンタクト:
- Danielle Wendler
- 電話番号:410-502-5140
- メール:JHCTN@jhmi.edu
-
コンタクト:
- Chelsea Miralles
- 電話番号:4109559923
- メール:cmirall1@jhmi.edu
-
主任研究者:
- Aliyah Pabani, MD
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Eligible patients include patients with malignancy treated with ICI, who have been diagnosed with a clinically significant irAE (grade 1-3 attributed to ICI per CTCAE v6.0) requiring interruption of ICI by the treating physician. This study is limited to patients with the following specific irAEs as IL-6R blockade has demonstrated effectiveness in these conditions. Specific toxicities eligible for inclusion are; arthritis, colitis, PMR, nephritis, pneumonitis, hepatitis, myositis
-
The risk/benefit profile must favor ICI rechallenge as deemed per treating oncologist
-
The irAE must have improved to grade 1 by CTCAE criteria v6.0 for at least 1 week (exception for patients who have endocrinopathies which will typically require lifelong hormone supplementation)
-
Be willing and able to provide informed consent/assent for the trial
-
Be ≥18 years of age on the day of signing informed consent
-
Female subject of childbearing potential must have a negative urine or serum pregnancy test within 2 weeks prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
-
Women of child-bearing potential (WOCBP):
- Agree to use contraception while participating in this study, and for a period of 6 months following last dose of Sarilumab or ICI, as effects of these agents on the developing human fetus are unknown. Men whose partner is a WOCBP must also agree to use contraception during this period. Negative pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within two weeks of registration. Women must not be breastfeeding or plan to breastfeed for the duration of therapy or 6 months after.
-
Males must practice true abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for 3 months after last dose of sarilumab, 120 days even if he has undergone a successful vasectomy
-
Have adequate organ function as described below
- Absolute neutrophil count (ANC) ≥500/mm3
- Platelets ≥ 50,000/mm3
- AST/ALT <=3× institutional upper limit of normal
-
Eastern Cooperative Oncology Group (ECOG) performance status 0-1
-
Completed informed consent process, including signing Institutional Review Board (IRB)/Ethics Committee (EC)-approved informed consent form.
-
Willing and able to comply with clinical trial instructions and requirements. Subjects must be competent to report AEs, understand the drug dosing schedule, and use of medications to control AEs
Exclusion Criteria:
- History of grade 4 irAE (attributed to ICI per CTCAE v6.0)
- History of cardiovascular or neurologic immune related adverse event
- Active or serious infections
- History of latent Tuberculosis (TB) or uncontrolled hepatitis B/C
- History of gastrointestinal perforation or diverticulitis
- Severe hepatic impairment (AST, ALT >3xULN; total bilirubin >1.5xULN)
- Significant hematological abnormalities
- On prednisone equivalent >10mg prior to first dose of trial treatment
- History of immunodeficiency disorder
- Treatment with a non-biologic immunosuppressive or immune-modulating drug (e.g. methotrexate, azathioprine, mycophenolate, cyclosporine, hydroxychloroquine, penicillamine) at time of enrollment
- Treatment with other immune-modulating biologic agents (e.g TNF-alpha inhibitors) within 8 weeks prior to enrollment
- History of anaphylaxis or IgE-mediated hypersensitivity to sarilumab or history of allergic reactions attributed to compounds of similar chemical or biologic composition to sarilumab.
- The subject must meet all of the inclusion criteria and none of the exclusion criteria.
No eligibility waivers will be granted.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Sarilumab with ICI
Sarilumab is dosed 200 mg subcutaneously every two weeks for a total of 24 weeks. ICI will be dosed by investigator's choice per standard of care for malignancy. ICI will be administered on day 1 of each 3 or 4 week cycle depending on the selected ICI agent. Administration of ICI will continue past the 24 week timepoint per discretion of the investigator. |
Sarilumab is dosed 200 mg subcutaneously every two weeks for a total of 24 weeks. ICI will be administered on day 1 of each 3 or 4 week cycle depending on the selected ICI agent. Administration of ICI will continue past the 24 week timepoint per discretion of the investigator. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Safety as assessed by Absence of any grade ≥2 Immune Related Adverse Event (irAE)
時間枠:From enrollment to the end of treatment at 53 weeks
|
Absence of any grade ≥2 Immune Related Adverse Event (irAE) in the 3 months after ICI rechallenge, defined as grade ≥2 adverse event attributed to ICI by CTCAE v6.0 |
From enrollment to the end of treatment at 53 weeks
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Safety and tolerability as assessed by occurrence of adverse events
時間枠:From enrollment to the end of treatment at 53 weeks
|
Safety and tolerability will be measured by occurrence of grade ≥3 adverse events as measured by CTCAE v6.0 and patient reported outcomes (PROs) as assessed by PRO-CTCAE v1.0. |
From enrollment to the end of treatment at 53 weeks
|
|
Absence of Serious immune-related adverse event
時間枠:From enrollment to the end of treatment at 53 weeks
|
To assess to the safety of Immune Checkpoint Inhibitor (ICI) rechallenge with sarilumab with respect to serious irAE of grade ≥2 in patients with a history of non- cardiovascular and non-neurologic clinically significant irAEs. |
From enrollment to the end of treatment at 53 weeks
|
|
Efficacy as assessed by progression free survival
時間枠:From enrollment to the end of treatment at 53 weeks
|
Cancer outcomes will be measured by progression free survival (PFS). PFS is defined as the time from first dose of sarilumab + ICI rechallenge until investigator-assessed radiological progressive disease (PD) or death, whichever comes first. |
From enrollment to the end of treatment at 53 weeks
|
|
Efficacy as assessed by Overall survival
時間枠:From enrollment to the end of treatment at 53 weeks
|
Cancer outcomes will be measured by overall survival (OS).Overall survival is defined as the time from first dose of sarilumab + ICI rechallenge until death. |
From enrollment to the end of treatment at 53 weeks
|
協力者と研究者
スポンサー
スポンサー
協力者
協力者
捜査官
捜査官
- 主任研究者:Aliyah Pabani, MD、Johns Hopkins University
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- J2687
- 15845 (その他の助成金/資金番号:Robert A. Winn Excellence in Clinical Trials Award)
- IRB00559848 (その他の識別子:Johns Hopkins IRB)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。